【个人简介】

孟昭杰，博士，广州医科大学南山学者特聘教授，呼吸疾病全国重点实验室课题组负责人（PI）、博士生导师、博士后合作导师。2014年获吉林大学博士学位，曾在美国哈佛大学医学院附属布莱根妇女医院及加州大学河滨分校从事博士后研究，2023年加入广州医科大学呼吸疾病全国重点实验室。长期致力于心肺血管稳态的免疫与代谢调控机制研究，重点围绕肺动脉高压、肺血管重构及相关心血管代谢性疾病开展基础与转化研究。入选国家级海外引才专项、广东省重大人才工程青年拔尖人才项目。现任广东省呼吸与健康学会肺栓塞与肺动脉高压专业委员会常务委员。联系方式mengzj@gzhmu.edu.cn, https://www.sklrd.cn/show.php?id=3262

【研究方向】

1.肺血管疾病发生发展的基础与转化研究

2.肺动脉高压的免疫与代谢调控机制

3.肺血管疾病关键靶点发现与创新治疗策略

【科研项目】

1.国家自然科学基金面上项目, 嗜酸性粒细胞来源的ECP活化肺动脉内皮细胞BMPR/Smad信号通路改善肺动脉高压血管重构的机制研究，2025-01-01至2028-12-31，49万，在研，主持。

2.广州省自然科学基金面上项目，嗜酸性粒细胞阳离子ECP通过特异性识别BMPR关键位点调控肺动脉平滑肌，2026-01-01至2028-12-31，10万，在研，主持。

3.高原医学教育部重点实验室开放课题，高原低氧环境下嗜酸性粒细胞过氧化物EPX识别ACVR关键位点调控肺血管重构的机制及靶向干预研究。2026-04-01至2027-03-31，5万，在研，主持。

【代表性论文及著作】

1.Xing-Yue Xu, Huan Yu, Maolin Wang, Feng-Rong Zhang, Mei Liu, Ji-Cheng Yang, Xian-Yu Li, Hong-Jun Yang, Zhaojie Meng. Colon-targeted chitosan-gold nanoparticles loaded with Pueraria flavonoids for ulcerative colitis therapy via barrier repair and immune modulation. Int J Biol Macromol. 2026 Jan;339(Pt 2):150084. IF=8.6

2.Zhaojie Meng*, Shuya Zhang*, Wei Li*, Yunzhe Wang, Minjie Wang, Xin Liu, Cong-Lin Liu, Sha Liao, Tianxiao Liu, Chongzhe Yang, Jes S Lindholt, Lars M Rasmussen, Lasse M Obel, Jane Stubbe, Axel C Diederichsen, Yong Sun, Yabing Chen, Paul B Yu, Peter Libby, Guo-Ping Shi, Junli Guo. Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis. Eur Heart J. 2023 Aug 1;44(29):2763-2783. *Contributed equally. IF=37.6

3.Tianxiao Liu*, Zhaojie Meng*, Jing Liu*, Jie Li, Yuanyuan Zhang, Zhiyong Deng, Songyuan Luo, Minjie Wang, Qin Huang, Shuya Zhang, Pauline Fendt, Julie Devouassoux, Dazhu Li, Andrew Neil James McKenzie, Matthias Nahrendorf, Peter Libby, Junli Guo, Guo-Ping Shi.Group 2 innate lymphoid cells protect mouse heart from myocardial infarction injury via interleukin 5, eosinophils, and dendritic cells. Cardiovasc Res. 2023 May 2;119(4):1046-1061. *Contributed equally. IF=13.3

4.Sandro Satta*, Zhaojie Meng*, Rebecca Hernandez, Susana Cavallero, Tong Zhou, Tzung K Hsiai, Changcheng Zhou. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages. Theranostics. 2022 Mar 6;12(6):2639-2657. *Contributed equally. IF=13.3

5.Yipeng Sui*, Zhaojie Meng*, Jianzhong Chen, Jingwei Liu, Rebecca Hernandez, Miko B Gonzales, Taesik Gwag, Andrew J Morris, Changcheng Zhou.Effects of Dicyclohexyl Phthalate Exposure on PXR Activation and Lipid Homeostasis in Mice. Environ Health Perspect. 2021 Dec;129(12):127001. *Contributed equally. IF=9.8

6.Zhaojie Meng, Yang Yu, Yining Zhang, Xuehan Yang, Xiaoyan Lv, Fengying Guan, Grant M Hatch, Ming Zhang, Li Chen. Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase. Int J Biol Sci. 2020 Jul 19;16(14):2527-2541. IF=10

7.Taesik Gwag*, Zhaojie Meng*, Yipeng Sui, Robert N Helsley, Se-Hyung Park, Shuxia Wang, Richard N Greenberg, Changcheng Zhou. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J Hepatol. 2019 May;70(5):930-940. *Contributed equally. IF=33

8.Zhaojie Meng*, Taesik Gwag*, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou. The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling. JCI Insight. 2019 Feb 7;4(3):e125657. *Contributed equally. IF=6.1

【所获荣誉和奖励】

1.国家级海外引才专项

2.广东省重大人才工程青年拔尖人才项目